{
  "docId": "019de076-3901-734c-833f-b5b0e2d3aa41",
  "docSlug": "e86c5f257c7f518e1f9c16c922f96c7d",
  "documentTitle": "Exscientia | Investor Presentation Deck | 76 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 76,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a table to highlight the unique value proposition of four specific clinical programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-3901-734c-833f-b5b0e2d3aa41/9",
  "deckHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41",
  "deckJsonHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41.json",
  "deckAnchorHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.45,
        "x": 0.076,
        "y": 0.945
      },
      "kind": "source-note",
      "text": "Does not include Exscientia-designed programmes that entered clinical trials through DSP collaboration",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2a548ff-bc8b-4637-8b04-55de8753e2fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.904,
        "x": 0.048,
        "y": 0.25
      },
      "kind": "table",
      "text": "Target, Phase, Target Market, Key Differentiation; CDK7, Phase 1/2, Multiple relapsed/refractory solid tumour indications, Precision designed PK/PD specific for mechanism. Identification of high-grade responders; PKC-theta, Phase 1, Multiple immunology indications, Better selectivity, improvements in whole blood potency and predicted human dose <200mg/day; LSD1, IND-enabling, SCLC, AML and potential additional indications, Uniquely combines reversibility with brain penetration, together with PK profile to optimise therapeutic index; MALT1, IND-enabling, Multiple haematology indications, Solved potential dose-limiting toxicity issue present in competitor compounds. Precision medicine platform to factor in likely responding groups",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d25981b3-1019-4ac2-b0e5-fa468aac033d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.48,
        "x": 0.076,
        "y": 0.14
      },
      "kind": "title",
      "text": "Differentiated through design and personalised medicine",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62262d19-8753-4b96-a7cb-90c1046eb595",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.076,
        "y": 0.068
      },
      "kind": "title",
      "text": "Why are our clinical candidates different?",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "515c43c0-04dd-4f41-87f9-098be1ac8f1d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "06f6918f-61c6-46f3-9b76-8cd6fa7f1812",
      "evidence": "table/data: Target, Phase, Target Market, Key Differentiation",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 9,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "169b62e8-66d6-4642-86a7-8c9f8da6f85f",
      "evidence": "The deck presents a clear problem statement and solution",
      "position": 0,
      "objective": "What is the cost of not improving clinical trial success rates?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}